Epigeneres has pioneered and developed certain nanotechnology and biomimicry based processes and is creating cutting-edge medicines and nutraceuticles to help patients. We are creating medication which is curing through gene repair and in-vivo stem cell

population increase using some proprietary technologies that we have created. Nemawashi - Target the root cause of the diseases and don’t just treat symptoms; solve the problem at the seed stage

Nanotechnology Based delivery mechanism

Epigeneres has created a nanotechnology based platform (US process patent pending) wherein we are able to greatly improve the therapeutic bio-availability and increase the half-life of the active molecule from a natural or synthetic source.

Furthermore we are making the molecule electrolytically compatible with genes and have had favourable results in terms of targeting specific genes. Our platform greatly improves the bioavailability and effectiveness of our molecule.

We have successfully shown the increase we are able to achieve with the therapeutic delivery of two nucleic acid polymers. We have a promising pipeline of 6 NCEs where we believe we will be able to significantly increase the bioavailability of the active molecule.

Our key focus has been with an extremely active molecule of resveratrol though we are also working on other promising molecules that have a similar potential using our platform.

In-vivo increase in Stem cell population.

Stem cells can divide and multiply to produce further stem cells and/or differentiate into specialized cells that form the various tissues and organs in our bodies. In contrast to embryonic stem cells, which differentiate into all the specialized cells in a developing embryo, adult stem cells repair and replenish various tissues in adult organisms. Thus, adult stem cells play a primary role in the maintenance of tissue health throughout our lives.

We have been working on research of how to increase the natural stem cell populations through the activation of specific genes which can result in in-vivo increase in stem cell population.

One of the primary signaling pathways that regulate the self-renewal and differentiation of adult stem cells is the Wnt pathway, a term which refers to a group of signal transduction pathways that play a crucial role in tissue health, ranging from formation to replenishment and from repair to regeneration of various tissues. Conversely, the dysregulation of the Wnt pathway in a particular tissue almost always leads to a disease of that tissue. The ability to modulate the Wnt pathway, and thereby recover and restore the health of diseased tissues, presents significant opportunities in regenerative therapeutics.

Wnt pathway has been extensively studied over the last three decades, and also has been implicated in hundreds of diseases, primarily in oncology and various degenerative conditions.

The focus of Epigeneres's technology platform is on the ability to modulate the Wnt pathway in select tissues with small molecules; our platform is not an "In-vitro stem cell therapy." To date, we have discovered numerous new biological processes related to the Wnt pathway, identified novel biological targets, and developed small-molecule drugs that modulate Wnt activity. Our top priority at Epigeneres is to translate this unique biological know-how into medical solutions for patients in need.